The ability of the IOS-1002 molecule to target LILRB1 and LILRB2 receptors simultaneously is an advantage that increases the pattern of immune cell activation and decreases the likelihood of tumor resistance by receptor substitution. This evidence concerns the gene LILRB1 and neoplasm.